Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement

Published:2021-01-11 Issue:3 Volume:39 Page:419-422
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

de‐la‐Fuente Cristina¹,Nuñez Fidel²,Cortés‐Romera Montserrat³,Franch‐Sarto Mireia¹,Ribera Josep‐Maria¹,Sancho Juan‐Manuel¹^ORCID

Affiliation:

1. Department of Hematology Institut Català d’Oncologia‐Hospital Germans Trias i Pujol, Josep Carreras Research Institute Badalona Spain

2. MRI Unit Institut de Diagnòstic per la Imatge, Hospital Germans Trias i Pujol Badalona Spain

3. Department of PET/CT‐Nuclear Medicine (IDI) Hospital de Bellvitge, Hospitalet de Llobregat Barcelona Spain

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2836

Reference18 articles.

1. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

2. Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

3. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma

4. Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant

5. Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature;Leukemia & Lymphoma;2024-09-03

2. Результаты терапии первичной медиастинальной В-крупноклеточной лимфомы. Опыт МРНЦ им. А.Ф. Цыба (Обнинск);Clinical Oncohematology;2024-07-01

3. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era;Hematological Oncology;2022-12-08

4. Antineoplastics;Reactions Weekly;2022-01

5. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy;Expert Review of Anticancer Therapy;2021-08-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3